Literature DB >> 11230410

In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi.

A Espinel-Ingroff1.   

Abstract

The NCCLS proposed standard M38-P describes standard parameters for testing the fungistatic antifungal activities (MICs) of established agents against filamentous fungi (molds); however, standard conditions are not available for testing their fungicidal activities (minimum fungicidal or lethal concentrations [MFCs]). This study evaluated the in vitro fungistatic and fungicidal activities of voriconazole, itraconazole, and amphotericin B against 260 common and emerging molds (174 Aspergillus sp. isolates [five species], 23 Fusarium sp. isolates [three species], 6 Paecilomyces lilacinus isolates, 6 Rhizopus arrhizus isolates, 23 Scedosporium sp. isolates, 23 dematiaceous fungi, and 5 Trichoderma longibrachiatum isolates). MICs were determined by following the NCCLS M38-P broth microdilution method. MFCs were the lowest drug dilutions that resulted in fewer than three colonies. Voriconazole showed similar or better fungicidal activity (MFC at which 90% of isolates tested are killed [MFC(90)], 1 to 2 microg/ml) than the reference agents for Aspergillus spp. with the exception of Aspergillus terreus (MFC(90) of voriconazole and amphotericin B, >8 microg/ml). The voriconazole geometric mean (G mean) MFC for Scedosporium apiospermum was lower (2.52 microg/ml) than those of the other two agents (5.75 to 7.5 microg/ml). In contrast, amphotericin B and itraconazole G mean MFCs for R. arrhizus were 2.1 to 2.2 microg/ml, but that for voriconazole was >8 microg/ml. Little or no fungicidal activity was shown for Fusarium spp. (2 to >8 microg/ml) and Scedosporium prolificans (>8 microg/ml) by the three agents, but voriconazole had some activity against P. lilacinus and T. longibrachiatum (G mean MFCs, 1.8 and 4 microg/ml, respectively). The fungicidal activity of the three agents was similar (G mean MFC, 1.83 to 2.36 microg/ml) for the dematiaceous fungi with the exception of the azole MFCs (>8 microg/ml) for some Bipolaris spicifera and Dactylaria constricta var. gallopava. These data extend and corroborate the available fungicidal results for the three agents. The role of the MFC as a predictor of clinical outcome needs to be established in clinical trials by following standardized testing conditions for determination of these in vitro values.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11230410      PMCID: PMC87856          DOI: 10.1128/JCM.39.3.954-958.2001

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  31 in total

1.  Comparative in-vitro activity of voriconazole (UK-109,496) and six other antifungal agents against clinical isolates of Scedosporium prolificans and Scedosporium apiospermum.

Authors:  M Cuenca-Estrella; B Ruiz-Díez; J V Martínez-Suárez; A Monzón; J L Rodríguez-Tudela
Journal:  J Antimicrob Chemother       Date:  1999-01       Impact factor: 5.790

2.  In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole.

Authors:  D A Sutton; S E Sanche; S G Revankar; A W Fothergill; M G Rinaldi
Journal:  J Clin Microbiol       Date:  1999-07       Impact factor: 5.948

3.  The emerging role of Fusarium infections in patients with cancer.

Authors:  E Anaissie; H Kantarjian; J Ro; R Hopfer; K Rolston; V Fainstein; G Bodey
Journal:  Medicine (Baltimore)       Date:  1988-03       Impact factor: 1.889

4.  In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi.

Authors:  E M Johnson; A Szekely; D W Warnock
Journal:  J Antimicrob Chemother       Date:  1998-12       Impact factor: 5.790

5.  Quality control limits for broth microdilution susceptibility tests of ten antifungal agents.

Authors:  A L Barry; M A Pfaller; S D Brown; A Espinel-Ingroff; M A Ghannoum; C Knapp; R P Rennie; J H Rex; M G Rinaldi
Journal:  J Clin Microbiol       Date:  2000-09       Impact factor: 5.948

6.  Microdilution susceptibility testing of amphotericin B, itraconazole, and voriconazole against clinical isolates of Aspergillus and Fusarium species.

Authors:  S Arikan; M Lozano-Chiu; V Paetznick; S Nangia; J H Rex
Journal:  J Clin Microbiol       Date:  1999-12       Impact factor: 5.948

7.  In vitro activities of voriconazole, itraconazole, and amphotericin B against Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma capsulatum.

Authors:  R K Li; M A Ciblak; N Nordoff; L Pasarell; D W Warnock; M R McGinnis
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

8.  Comparative study of susceptibilities of germinated and ungerminated conidia of Aspergillus fumigatus to various antifungal agents.

Authors:  E K Manavathu; J Cutright; P H Chandrasekar
Journal:  J Clin Microbiol       Date:  1999-03       Impact factor: 5.948

Review 9.  Invasive aspergillosis caused by Aspergillus ustus: case report and review.

Authors:  P E Verweij; M F van den Bergh; P M Rath; B E de Pauw; A Voss; J F Meis
Journal:  J Clin Microbiol       Date:  1999-05       Impact factor: 5.948

10.  Disseminated Aspergillus ustus infection following cardiac surgery.

Authors:  L M Weiss; W A Thiemke
Journal:  Am J Clin Pathol       Date:  1983-09       Impact factor: 2.493

View more
  62 in total

1.  Successful control of disseminated Scedosporium prolificans infection with a combination of voriconazole and terbinafine.

Authors:  B P Howden; M A Slavin; A P Schwarer; A M Mijch
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-02-14       Impact factor: 3.267

2.  Comparison of in vitro activities of 17 antifungal drugs against a panel of 20 dermatophytes by using a microdilution assay.

Authors:  Bertrand Favre; Bettina Hofbauer; Kwang-Soo Hildering; Neil S Ryder
Journal:  J Clin Microbiol       Date:  2003-10       Impact factor: 5.948

Review 3.  In vitro analyses, animal models, and 60 clinical cases of invasive Aspergillus terreus infection.

Authors:  William J Steinbach; John R Perfect; Wiley A Schell; Thomas J Walsh; Daniel K Benjamin
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

Review 4.  Determination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization.

Authors:  M A Pfaller; D J Sheehan; J H Rex
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

5.  Activity of deferasirox in Mucorales: influences of species and exogenous iron.

Authors:  Russell E Lewis; Georgios N Pongas; Nathaniel Albert; Ronen Ben-Ami; Thomas J Walsh; Dimitrios P Kontoyiannis
Journal:  Antimicrob Agents Chemother       Date:  2010-10-18       Impact factor: 5.191

6.  In vitro antifungal susceptibility of Sporothrix globosa isolates from Jilin Province, northeastern China: comparison of yeast and mycelial phases.

Authors:  Yang Song; Shanshan Li; Ying Shi; Lipei Zhao; Yu Cui; Lei Yao; Yu Zhen; Ruili Chen; Yan Cui
Journal:  Braz J Microbiol       Date:  2020-06-17       Impact factor: 2.476

7.  Differential fungicidal activities of amphotericin B and voriconazole against Aspergillus species determined by microbroth methodology.

Authors:  Joseph Meletiadis; Charalampos Antachopoulos; Theodouli Stergiopoulou; Spyros Pournaras; Emmanuel Roilides; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2007-06-18       Impact factor: 5.191

8.  Keratitis caused by Scedosporium apiospermum successfully treated with a cornea transplant and voriconazole.

Authors:  Eric Nulens; Cathrien Eggink; Antonius J M M Rijs; Pieter Wesseling; Paul E Verweij
Journal:  J Clin Microbiol       Date:  2003-05       Impact factor: 5.948

9.  In vitro susceptibility of environmental isolates of Exophiala dermatitidis to five antifungal drugs.

Authors:  Ana Paula Miranda Duarte; Fernando Carlos Pagnocca; Noemi Carla Baron; Marcia de Souza Carvalho Melhem; Gislene Aparecida Palmeira; Dejanira de Franceschi de Angelis; Derlene Attili-Angelis
Journal:  Mycopathologia       Date:  2012-11-16       Impact factor: 2.574

10.  Pharmacokinetics of liposomal amphotericin B in pleural fluid.

Authors:  Brad Moriyama; Parizad Torabi-Parizi; Alexandra K Pratt; Stacey A Henning; Gennethel Pennick; Yvonne R Shea; Sinchita Roy Chowdhuri; Michael G Rinaldi; A John Barrett; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2010-01-19       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.